+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Analysis: Natrecor

  • PDF Icon

    Drug Pipelines

  • 12 Pages
  • February 2018
  • Region: Global
  • Citeline
  • ID: 4489135
Drug Overview

Natrecor (nesiritide; Johnson & Johnson) is a recombinant form of human brain natriuretic peptide (BNP), a circulating hormone of cardiac origin indicated for the treatment of patients with acute decompensated heart failure (ADHF) who have dyspnea at rest or with minimal activity. BNP is naturally secreted by the ventricular myocardium in response to volume overload and increased filling pressure. It binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3’5’-cyclic monophosphate (cGMP) and smooth muscle cell relaxation.

cGMP serves as a second messenger to dilate veins and arteries, and Natrecor causes natriuresis and a reduction in intravascular volume. The natriuretic effect results from a direct inhibition of sodium absorption in the renal collecting duct, increased glomerular infiltration, and inhibited aldosterone production and secretion. This produces a prompt fall in systemic vascular resistance and pulmonary capillary wedge pressure, associated with rapid clinical improvement in ADHF.

Table of Contents

1 Product Profiles
  • Natrecor: Acute decompensated heart failure (ADHF)

List of Figures
Figure 1: Natrecor for ADHF - SWOT analysis
Figure 2: The author’s drug assessment summary for Natrecor in ADHF
Figure 3: The author’s drug assessment summary for Natrecor in ADHF

List of Tables
Table 1: Natrecor drug profile
Table 2: Natrecor Phase III data in ADHF

Companies Mentioned

  • Johnson & Johnson